This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Poulter, N. Articles by McInnes, G. Search for Related Content PubMed PubMed Citation Articles by Poulter, N. Articles by McInnes, G. Social Bookmarking                         What's this?

Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers

A mini-symposium held at the British Hypertension Society Meeting, September 2005

Alun D Hughes

Clinical Pharmacology, NHLI Division, Faculty of Medicine, Imperial College London, London

Bryan Williams

Cardiovascular Research Institute, Faculty of Medicine & Biological Sciences, University of Leicester Clinical Sciences Building, Leicester Royal Infirmary, Leicester

Adrian JB Brady

Department of Medical Cardiology, Glasgow Royal Infirmary

Gordon McInnes

University of Glasgow, Department of Medicine and Therapeutics, Western Infirmary Glasgow

References

• Levy BI How to explain the differences between renin angiotensin system modulators. Am J Hypertens 2005;18(9 Pt 2): 134S-141S.[Web of Science][Medline] [Order article via Infotrieve]
• Santos RA, Ferreira AJ, Pinheiro SV, Sampaio WO, Touyz R., Campagnole-Santos MJ Angiotensin-(1-7) and its receptor as a potential target for new cardiovascular drugs. Expert Opin Investig Drugs 2005;14:1019-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pagliaro P., Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005;19:77-87.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Doggrell SA Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin Pharmacother 2002;3:1543-56.[CrossRef][Medline] [Order article via Infotrieve]
• Reid JL Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? JRAAS 2005;6:15-24.[Medline] [Order article via Infotrieve]
• Henrion D., Kubis N., Levy BI Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 2001;38:1150-7.[Abstract/Free Full Text]
• Chai SY, Fernando R., Peck G., Ye SY, Mendelsohn FA, Jenkins TA, Albiston AL The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004;61:2728-37.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Carey RM Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005;45:840-44.[Free Full Text]
• Ferrario CM, Trask AJ, Jessup JA Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-2290.[Abstract/Free Full Text]
• Pagliaro P., Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005;19:77-87.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Li W., Moore MJ, Vasilieva N., Sui J., Wong SK, Berne MA, Somasundaran M., Sullivan JL, Luzuriaga K., Greenough TC, Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-54.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Campbell DJ, Krum H., Esler MD Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111:315-20.[Abstract/Free Full Text]
• Fleming I., Kohlstedt K., Busse R. New fACEs to the renin-angiotensin system. Physiology (Bethesda) 2005;20:91-5.[CrossRef][Medline] [Order article via Infotrieve]
• Schupp M., Clemenz M., Gineste R. et al. Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulators with Angiotensin Receptor Blocking Activity. Diabetes 2005; 54:3442-52.[Abstract/Free Full Text]
• Wilms H., Rosenstiel P., Unger T., Deuschl G., Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005;5:245-53.[CrossRef][Medline] [Order article via Infotrieve]
• Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD Evidence against a major role for angiotensin converting enzymerelated carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 2004;22:1971-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fox KM; European trial on reduction of cardiac events with perindopril in stable coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Du X., McNamee R., Cruickshank K. Stroke risk from multiple risk factors combined with hypertension: a primary care based case-control study in a defined population of northwest England. Annals of Epidemiology 2000;10:380-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19.[Abstract/Free Full Text]
• Pfeffer M., McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.[Abstract/Free Full Text]
• Verma S., Strauss M., Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-9.[Free Full Text]
• Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50:272-98.[Abstract/Free Full Text]
• Blood Pressure Lowering Treatment Trialist Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;62:1527-35.
• Dahlöf B., Devereux RB, Kjeldson SE et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Julius S.,KjeldsenSE, WeberM etal, forthe VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial. Lancet 2004;363:2022-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen study among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;3581:1033-41.
• Schrader J., Lüders S., Kulschewski A. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218-26.[Abstract/Free Full Text]
• Schrader J., Lüders S., Kulschewski A. et al; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34:1699-703.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 2, 104-121 (2006)
DOI: 10.3317/jraas.2006.008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Poulter, N. Articles by McInnes, G. Search for Related Content PubMed PubMed Citation Articles by Poulter, N. Articles by McInnes, G. Social Bookmarking                         What's this?